ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade
NEW YORK, December 30, 2025, 13:35 ET — Regular session Shares of ADMA Biologics fell 3.7% to $18.40 in afternoon trading on Tuesday, a steeper drop than the broader biotech group. The SPDR S&P Biotech ETF was down about 1.3%. The pullback came as U.S. stocks steadied in holiday-thin trading ahead of minutes from the Federal Reserve’s December policy meeting, after the central bank delivered a 25-basis-point cut this month. Mark Hackett, chief market strategist at Nationwide, described recent positioning as “a healthy rebalancing of allocations.” Reuters Biotechnology shares were among the laggards, with the NYSE Arca Biotechnology Index down